Biostax Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Noreen Griffin

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure2yrs
CEO ownership9.2%
Management average tenure2.8yrs
Board average tenure5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Noreen Griffin's remuneration changed compared to Biostax's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$2m

Jun 30 2024n/an/a

-US$2m

Mar 31 2024n/an/a

-US$2m

Dec 31 2023US$112kn/a

-US$2m

Sep 30 2023n/an/a

-US$2m

Jun 30 2023n/an/a

-US$4m

Mar 31 2023n/an/a

-US$1m

Dec 31 2022n/an/a

-US$4m

Sep 30 2022n/an/a

-US$3m

Jun 30 2022n/an/a

US$2m

Mar 31 2022n/an/a

US$239k

Dec 31 2021n/an/a

US$4m

Sep 30 2021n/an/a

US$3m

Jun 30 2021n/an/a

US$4m

Mar 31 2021n/an/a

US$3m

Dec 31 2020n/an/a

US$2m

Sep 30 2020n/an/a

US$2m

Jun 30 2020n/an/a

-US$3m

Mar 31 2020n/an/a

-US$3m

Dec 31 2019US$536kUS$378k

-US$3m

Sep 30 2019n/an/a

-US$3m

Jun 30 2019n/an/a

-US$5m

Mar 31 2019n/an/a

-US$8m

Dec 31 2018US$500kUS$482k

-US$8m

Compensation vs Market: Insufficient data to establish whether Noreen's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Noreen's compensation has been consistent with company performance over the past year.


CEO

Noreen Griffin (72 yo)

2yrs
Tenure
US$111,742
Compensation

Ms. Noreen M. Griffin was Founder and Executive Vice President of Corporate Strategy at Statera Biopharma, Inc. (formerly known as Cytocom, Inc.) until October 2021. She is Founder of Biostax Corp. (former...


Leadership Team

NamePositionTenureCompensationOwnership
Noreen Griffin
Founder2yrsUS$111.74k9.21%
$ 1.6k
Kelly Wilson
President2.7yrsUS$285.96k18.08%
$ 3.1k
Glen Farmer
Chief Financial Officer2.9yrsUS$155.33k0.47%
$ 81.8
Robert Wilson
VP of Strategy & Director1.1yrsno data0.00058%
$ 0.1
Cynthia Douglas
Company Secretary3yrsno datano data
Joseph Fortunak
Vice President of Global Research & Development and Chemical Development12.3yrsno datano data
2.8yrs
Average Tenure
54.5yo
Average Age

Experienced Management: BTAX's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Wilson
VP of Strategy & Director3.2yrsno data0.00058%
$ 0.1
Nicholas Plotnikoff
Member of Advisory Boardno dataUS$16.20kno data
Robert Buckheit
Member of Scientific Advisory Boardno datano datano data
Joseph Chalil
Member of Medical & Clinical Advisory Board8.8yrsno datano data
Jill Smith
Member of Advisory Boardno datano datano data
Makarand Jawadekar
Member of Medical & Clinical Advisory Board8.8yrsno datano data
Terry Grossman
Member of Advisory Boardno datano datano data
Gary Blick
Member of Scientific Advisory Board6.9yrsno datano data
Mary Clay Reynolds
Director1.8yrsUS$4.00kno data
Roger Suro
Director1.7yrsUS$3.00kno data
5.0yrs
Average Tenure
62yo
Average Age

Experienced Board: BTAX's board of directors are considered experienced (5 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/23 14:16
End of Day Share Price 2025/04/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biostax Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ajay TandonSeeThruEquity, LLC